SCM
RVMD icon

SCS Capital Management’s Revolution Medicines RVMD Stock Holding History

SCS Capital Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$724K Hold
3,867
– – 0.01% 326
2026
Q1 		$376K Hold
3,867
– – ﹤0.01% 383
2025
Q4 		$308K Buy
+3,867
New +$254K ﹤0.01% 425

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

SCS Capital Management's RVMD Position: Q2 2026 in Review

SCS Capital Management held its Revolution Medicines (RVMD) position steady in Q2 2026 at 3,867 shares worth $724K. The position accounts for 0.01% of the portfolio, ranked #326.

SCS Capital Management first reported a position in RVMD in Q4 2025 and has held it in 3 quarters since. 692 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • SCS Capital Management held 3,867 shares of Revolution Medicines worth $724K as of Q2 2026.
  • SCS Capital Management left its Revolution Medicines share count unchanged in Q2 2026.
  • Revolution Medicines made up 0.01% of SCS Capital Management's portfolio in Q2 2026, its #326 holding.
  • SCS Capital Management first reported a position in Revolution Medicines in Q4 2025 and has held it in 3 quarters since.
  • 692 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on SCS Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.